Evidence for a raised concentration of a circulating sodium transport inhibitor in essential hypertension.
Graham A. MacGregor(Queen Mary University of London), H. E. de Wardener(Charing Cross Hospital), S. Fenton(Charing Cross Hospital), Jamshid Alaghband‐Zadeh(Charing Cross Hospital), Nirmala D. Markandu(University of London), J E Roulston(Charing Cross Hospital)
Cited by 103
Related Papers
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
|The Lancet Diabetes & Endocrinology|2018|340
DOUBLE-BLIND STUDY OF THREE SODIUM INTAKES AND LONG-TERM EFFECTS OF SODIUM RESTRICTION IN ESSENTIAL HYPERTENSION
|The Lancet|1989|272
Structural Skin Capillary Rarefaction in Essential Hypertension
|Hypertension|1999|259